MedGenome, a leading global Genomic Diagnostic and Research Services company in South Asia, becomes the first to offer advanced genomics services using Illumina’s NovaSeq X Plus in South Asia.
Evotec SE announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement.
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership Read More »
Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $7.50 per share.
Mirum Pharmaceuticals, Inc. announced that on July 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,850 shares of common stock and 22,430 restricted stock units to ten new employees under Mirum’s 2020 Inducement Plan.
Acerus Pharmaceuticals Corporation announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act and its previously announced sale and investment solicitation process, the Company completed the previously announced transactions with First Generation Capital Inc. as successful bidder under the SISP.
Pixium Vision announces the agreement to extend the maturity date of the outstanding notes associated with the terminatedESGO financing facility
Zhejiang Doer Biologics Co., Ltd., a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announced that it has entered into a license agreement with BioNTech SE.
Doer Biologics Announces License Agreement with BioNTech Read More »
Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic disease, with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional
Innate Pharma SA announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial, evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma and Relapsed/Refractory Light-chain Amyloidosis 1.
Las mujeres con ECV experimentan retraso en el diagnóstico, tienen menos posibilidad de ser tratadas según guías, complicaciones y peores resultados que los hombres.
